Log in

NASDAQ:NLNKNewLink Genetics Stock Price, Forecast & News

-0.59 (-4.07 %)
(As of 05/29/2020 04:00 PM ET)
Today's Range
Now: $13.91
50-Day Range
MA: $9.07
52-Week Range
Now: $13.91
Volume26,443 shs
Average Volume547,540 shs
Market Capitalization$519.23 million
P/E RatioN/A
Dividend YieldN/A
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.
Read More
NewLink Genetics logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:NLNK



Sales & Book Value

Annual Sales$940,000.00
Book Value$2.11 per share


Net Income$-42,990,000.00
Net Margins-4,592.84%


Market Cap$519.23 million
Next Earnings DateN/A

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NLNK and its competitors with MarketBeat's FREE daily newsletter.

NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

How has NewLink Genetics' stock been impacted by COVID-19 (Coronavirus)?

NewLink Genetics' stock was trading at $1.2101 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NLNK shares have increased by 1,049.5% and is now trading at $13.91. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of NewLink Genetics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NewLink Genetics in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View analyst ratings for NewLink Genetics.

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative return on equity of 41.50%. View NewLink Genetics' earnings history.

Has NewLink Genetics been receiving favorable news coverage?

Media headlines about NLNK stock have trended extremely negative on Sunday, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NewLink Genetics earned a media sentiment score of -5.0 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutNewLink Genetics.

Who are some of NewLink Genetics' key competitors?

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Arbutus Biopharma (ABUS), Inovio Pharmaceuticals (INO), Opko Health (OPK), Synergy Pharmaceuticals (SGYP), SunPower (SPWR), Alibaba Group (BABA), Novavax (NVAX), Sarepta Therapeutics (SRPT), Cara Therapeutics (CARA) and Celldex Therapeutics (CLDX).

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the following people:
  • Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
  • Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
  • Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
  • Mr. Brian Wiley, Chief Commercial Officer (Age 51)
  • Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

How do I buy shares of NewLink Genetics?

Shares of NLNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $13.91.

How big of a company is NewLink Genetics?

NewLink Genetics has a market capitalization of $519.23 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42,990,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. NewLink Genetics employs 55 workers across the globe.

What is NewLink Genetics' official website?

The official website for NewLink Genetics is www.newlinkgenetics.com.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.